|
業務類別
|
-- |
|
業務概覽
|
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products. |
| 公司地址
| No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123 |
| 電話號碼
| +86 51262639909 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kintor.com.cn |
| 員工數量
| 168 |
| Dr. Xiang Ni |
Director and Chief Medical Officer |
-- |
29/04/2024 |
| Dr. Qun Lu |
Director and Chief Technology Officer |
-- |
29/04/2024 |
| Dr. Youzhi Tong |
Chairman of the Board and Chief Executive Officer |
-- |
29/04/2024 |
|
|
| Dr. Xiang Ni |
Director and Chief Medical Officer |
29/04/2024 |
| Ms. Wei Geqi |
Director |
29/04/2024 |
| Mr. Gao Weipeng |
Director |
29/04/2024 |
| Dr. Qun Lu |
Director and Chief Technology Officer |
29/04/2024 |
| Mr. Chengwei Liu |
Director |
29/04/2024 |
| Dr. Youzhi Tong |
Chairman of the Board and Chief Executive Officer |
29/04/2024 |
| Dr. Min Michael Xu |
Independent Director |
29/04/2024 |
| Mr. Wai Yim Wallace Yeung |
Independent Director |
29/04/2024 |
| Professor Liang Tong |
Independent Director |
29/04/2024 |
|
|
|
|
